Scholarlink

Background <p> Obstructive sleep apnea (OSA) and sarcopenia are common age-related conditions that significantly reduce quality of life. OSA is characterized by recurrent breathing interruptions and chronic intermittent hypoxia, while sarcopenia involves progressive loss of muscle mass and strength. Accumulating evidence indicates that chronic intermittent hypoxia and sleep fragmentation in OSA may promote muscle wasting via inflammatory pathways (e.g., NF-κB), oxidative stress, and impaired protein synthesis. Conversely, sarcopenia-related muscle weakness may worsen upper airway collapsibility, creating a vicious cycle. However, the molecular mechanisms linking OSA and sarcopenia remain poorly understood.</p> Methods <p> We performed differential expression analysis on OSA and sarcopenia datasets from the Gene Expression Omnibus (GEO) and used weighted gene co-expression network analysis (WGCNA) to identify candidate biomarkers, with functional enrichment assessed under false discovery rate (FDR) correction. A diagnostic model was constructed based on key genes and validated using receiver operating characteristic (ROC), calibration, and decision curves. Immune cell infiltration was analyzed using the CIBERSORT algorithm.</p> Results <p> We identified 123 differentially expressed genes shared by OSA and sarcopenia, enriched in pathways related to muscle function, cellular stress, metabolic disorders, and neurodegeneration. WGCNA identified ESF1, ZNF117, and C2orf49 as core genes. The diagnostic model showed high accuracy (area under the curve (AUC): 0.912 for OSA, and 0.967 for sarcopenia in training; 0.787 for OSA, and 0.744 for sarcopenia in validation). These genes were closely associated with pro-inflammatory immune cells.</p> Conclusion <p> This study identifies ESF1, ZNF117, and C2orf49 as potential shared biomarkers for OSA and sarcopenia. The robust diagnostic model and the observed tissue-specific gene dysregulation illuminate the systemic interplay between these conditions, offering insights for risk stratification and future mechanistic research.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of shared biomarkers for obstructive sleep apnea and sarcopenia via differential expression and WGCNA analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月5日

查看全文
  • Fei Jiang,
  • Yang Xu,
  • Bin Zheng,
  • Guang-Lei Zhang,
  • Ren-Hu Li

摘要

Background

Obstructive sleep apnea (OSA) and sarcopenia are common age-related conditions that significantly reduce quality of life. OSA is characterized by recurrent breathing interruptions and chronic intermittent hypoxia, while sarcopenia involves progressive loss of muscle mass and strength. Accumulating evidence indicates that chronic intermittent hypoxia and sleep fragmentation in OSA may promote muscle wasting via inflammatory pathways (e.g., NF-κB), oxidative stress, and impaired protein synthesis. Conversely, sarcopenia-related muscle weakness may worsen upper airway collapsibility, creating a vicious cycle. However, the molecular mechanisms linking OSA and sarcopenia remain poorly understood.

Methods

We performed differential expression analysis on OSA and sarcopenia datasets from the Gene Expression Omnibus (GEO) and used weighted gene co-expression network analysis (WGCNA) to identify candidate biomarkers, with functional enrichment assessed under false discovery rate (FDR) correction. A diagnostic model was constructed based on key genes and validated using receiver operating characteristic (ROC), calibration, and decision curves. Immune cell infiltration was analyzed using the CIBERSORT algorithm.

Results

We identified 123 differentially expressed genes shared by OSA and sarcopenia, enriched in pathways related to muscle function, cellular stress, metabolic disorders, and neurodegeneration. WGCNA identified ESF1, ZNF117, and C2orf49 as core genes. The diagnostic model showed high accuracy (area under the curve (AUC): 0.912 for OSA, and 0.967 for sarcopenia in training; 0.787 for OSA, and 0.744 for sarcopenia in validation). These genes were closely associated with pro-inflammatory immune cells.

Conclusion

This study identifies ESF1, ZNF117, and C2orf49 as potential shared biomarkers for OSA and sarcopenia. The robust diagnostic model and the observed tissue-specific gene dysregulation illuminate the systemic interplay between these conditions, offering insights for risk stratification and future mechanistic research.

Graphical Abstract